vincristine + dexamethasone + L-asparaginase + daunorubicin

VXLD is a four-drug chemotherapy combination regimen primarily used in the induction phase of treatment for pediatric acute lymphoblastic leukemia (ALL). The regimen consists of vincristine (a vinca alkaloid microtubule inhibitor), dexamethasone (a synthetic glucocorticoid corticosteroid), L-asparaginase (an enzyme that depletes extracellular asparagine), and daunorubicin (an anthracycline topoisomerase II inhibitor). By combining these agents, VXLD targets leukemic cells through multiple distinct pathways: disrupting mitotic spindle formation, inducing apoptosis via glucocorticoid receptor activation, starving cells of the essential amino acid asparagine, and causing DNA damage through intercalation and enzyme inhibition. This intensive combination is designed to rapidly reduce the leukemic cell burden and achieve complete remission in high-risk pediatric patients.

Other names

VXLD